[{"id":"194502d1-d83a-4669-a459-c99310c1bacf","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=acfc0b7d9c6d4b08859e47d954d8ec7e","created_at":"2026-06-27T01:57:16.403Z","updated_at":"2026-06-27T01:57:16.403Z","phase":"Phase 1","brief_title":"A Phase I clinical study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST2169 liposomes for injection in patients with KRAS G12D-mutant advanced solid tumors.","source_id_and_acronym":"CTR20240981","lead_sponsor":"Shanghai Allis Pharmaceutical Technology Co., Ltd.","biomarkers":" KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • MSI-H/dMMR • BRAF V600 • KRAS G12D • KRAS G12","tags":["KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • MSI-H/dMMR • BRAF V600 • KRAS G12D • KRAS G12"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"210387dc-81f7-4dfe-8076-842639d56f3e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=96e720e0c977413a9c1c7b41e127b31b","created_at":"2026-06-27T02:17:10.527Z","updated_at":"2026-06-27T02:17:10.527Z","phase":"Phase 2","brief_title":"A phase II clinical study evaluating the efficacy and safety of HL-085 capsules in combination with vemurafenib for the treatment of patients with BRAF V600E-mutant locally advanced or metastatic non-small cell lung cancer.","source_id_and_acronym":"CTR20231191","lead_sponsor":"Shanghai Kezhou Pharmaceutical Research \u0026 Development Co., Ltd. / Tianjin Binjiang Pharmaceutical Research \u0026 Development Co., Ltd.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 02/21/2024","start_date":" 02/21/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"5775d360-9076-47b8-b29d-d29780d8eeb0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=f3bc37a532d24d49aaa5bebfed2ae497","created_at":"2026-06-27T02:00:45.679Z","updated_at":"2026-06-27T02:00:45.679Z","phase":"Phase 2","brief_title":"A study evaluating the safety and pharmacokinetics of tiragolumab and atezolizumab fixed-dose combination (FDC) in patients with locally advanced, recurrent, or metastatic solid tumors.","source_id_and_acronym":"CTR20241480","lead_sponsor":"F. Hoffmann - La Roche Ltd / Roche (China) Investment Co., Ltd. / Genentech Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1 • TIGIT","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • BRAF V600E • EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • BRAF V600E • EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/25/2025","start_date":" 02/25/2025","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"63e9029a-0d18-429b-a8b6-77a67e958265","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=dc8642d7daff446e8f123a34f5f92740","created_at":"2026-06-27T01:59:13.080Z","updated_at":"2026-06-27T01:59:13.080Z","phase":"Phase 3","brief_title":"Clinical study of nimotuzumab in combination with trifluuridine tipiracil for the treatment of metastatic colorectal cancer","source_id_and_acronym":"CTR20241261","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Suspended","enrollment":" Enrollment 420","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6cf17c33-3020-4ad1-8dc8-b75be908ca63","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=209922557c87436497e8c555f788596d","created_at":"2026-06-27T02:24:52.692Z","updated_at":"2026-06-27T02:24:52.692Z","phase":"Phase 3","brief_title":"A randomized, controlled, open-label, multicenter phase III clinical trial evaluating the efficacy and safety of tolametinib in combination with vemurafenib for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.","source_id_and_acronym":"CTR20232218","lead_sponsor":"Shanghai Kezhou Pharmaceutical Research \u0026 Development Co., Ltd. / Tianjin Binjiang Pharmaceutical Research \u0026 Development Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"8370fa94-32b2-4b05-a683-c2166143ed75","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2790ec3894414396a7fa5101c6c42f31","created_at":"2026-06-27T02:02:05.738Z","updated_at":"2026-06-27T02:02:05.738Z","phase":"Phase 1/2","brief_title":"Phase Ib/IIa clinical trial of purisat mesylate for injection in patients with advanced solid tumors.","source_id_and_acronym":"CTR20241672","lead_sponsor":"Chengdu Zeling Biomedical Technology Co., Ltd.","biomarkers":" PD-L1 • BRAF • TMB • MSI • FGFR2","pipe":" | ","alterations":" BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600 • FGFR2 mutation","tags":["PD-L1 • BRAF • TMB • MSI • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600 • FGFR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • fulvestrant • exemestane • purinostat"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"c757c605-93f4-4952-9a82-b04f17332607","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a4205922764a480bb5fdf72d597f3e86","created_at":"2026-06-27T02:08:40.611Z","updated_at":"2026-06-27T02:08:40.611Z","phase":"Phase 1","brief_title":"An assessment of adverse events and the migration of intravenously (IV) ABBV-400 in adult subjects with unresectable locally advanced/metastatic colorectal cancer.","source_id_and_acronym":"CTR20242547","lead_sponsor":"AbbVie Inc. / AbbVie Medical Trading (Shanghai) Co., Ltd. / AbbVie Deutschland GmbH \u0026 Co. KG","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/14/2024","start_date":" 10/14/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"48c348af-8920-4d68-9737-04c50869bf42","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=97602e2ab9854ee89b817991140a3179","created_at":"2026-06-27T02:51:19.532Z","updated_at":"2026-06-27T02:51:19.532Z","phase":"Phase 2","brief_title":"A Phase IIb clinical trial comparing the efficacy and safety of omega-3 monoclonal antibody in combination with anti-PD-1 monoclonal antibody and FOLFIRI, versus omega-3 monoclonal antibody or cetuximab in combination with FOLFIRI, in patients with RAS wild-type advanced colorectal cancer.","source_id_and_acronym":"CTR20222853","lead_sponsor":"Shanghai Saiyuan Biotechnology Co., Ltd.","biomarkers":" PD-L1 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • KRAS wild-type • NRAS wild-type","tags":["PD-L1 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"54ff079c-1bdb-45e0-ac0b-d22aeb8567a5","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=50865f54fe3d4577b9e68a7dad9b8b32","created_at":"2026-06-27T03:07:16.616Z","updated_at":"2026-06-27T03:07:16.616Z","phase":"Phase 2","brief_title":"A phase II clinical trial evaluating HL-085 capsules in combination with vemurafenib tablets for the treatment of patients with advanced melanoma harboring BRAF V600E/V600K mutations.","source_id_and_acronym":"CTR20211726","lead_sponsor":"Shanghai Kezhou Pharmaceutical Research \u0026 Development Co., Ltd. / Tianjin Binjiang Pharmaceutical Research \u0026 Development Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"120b070e-a575-4d06-97cb-9b381227cf3d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=279a55a5d0ae4c07b8e50c5ecf8dfb63","created_at":"2026-06-27T03:17:03.129Z","updated_at":"2026-06-27T03:17:03.129Z","phase":"Phase 2","brief_title":"A Phase II clinical trial of FCN-159 tablets in patients with recurrent or progressive low-grade gliomas.","source_id_and_acronym":"CTR20213289","lead_sponsor":"Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. / Chongqing Fuchuang Pharmaceutical Research Co., Ltd.","biomarkers":" BRAF • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF fusion","tags":["BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fumaining (luvometinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"9850a3c8-83a6-467a-894d-fae04b8dc329","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ee798afd87904bb0a830366c6b9794d9","created_at":"2026-06-27T03:29:19.685Z","updated_at":"2026-06-27T03:29:19.685Z","phase":"Phase 3","brief_title":"A phase III clinical study comparing the efficacy and safety of A140 and Erbitux® in combination with mFOLFOX6 regimen as first-line treatment for patients with RAS wild-type metastatic colorectal cancer.","source_id_and_acronym":"CTR20202451","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 686","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"a8d87328-e6fa-4560-85b8-695860657601","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=590939ba857c4d2683e3f4fa7080dec3","created_at":"2026-06-27T03:52:18.104Z","updated_at":"2026-06-27T03:52:18.104Z","phase":"Phase 3","brief_title":"Phase III trial of QL1203 plus mFOLFOX6 versus placebo plus mFOLFOX6 for the treatment of metastatic colorectal cancer.","source_id_and_acronym":"CTR20191318","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • QL1203 • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"bff3ef5c-9239-49f2-bd4e-ed95da4ad071","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=7c0b861ee9fa42f9912bcd420686a843","created_at":"2026-06-27T03:30:26.013Z","updated_at":"2026-06-27T03:30:26.013Z","phase":"Phase 1","brief_title":"An exploratory clinical study evaluating the combination of fully human anti-PD-L1 antibody injection (LDP) and recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection (CDP1) in patients with advanced malignant tumors.","source_id_and_acronym":"CTR20202642","lead_sponsor":"Baochuan Biomedical Technology (Shanghai) Co., Ltd.","biomarkers":" BRAF • CUX1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"f38a94c1-be32-40a3-acd3-da2748ce6e10","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=73a905cd082e4dbe9e09fd15efebecdc","created_at":"2026-06-27T03:14:01.927Z","updated_at":"2026-06-27T03:14:01.927Z","phase":"Phase 2","brief_title":"An open-label, multicenter phase II clinical trial evaluating the efficacy, safety, and pharmacokinetics (PK) of HLX208 tablets in BRAF V600E-mutant metastatic colorectal cancer (mCRC).","source_id_and_acronym":"CTR20212777","lead_sponsor":"Suzhou Runxin Biotechnology Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • PTEN mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • RX208"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"f4667e9c-9ee4-4096-92d6-87ed3e422426","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=845068be53054f96bbc16bac6724d314","created_at":"2026-06-27T03:30:26.566Z","updated_at":"2026-06-27T03:30:26.566Z","phase":"Phase 1","brief_title":"An exploratory clinical study evaluating the combination of fully human anti-PD-L1 antibody injection (LDP) and recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection (CDP1) in patients with advanced malignant tumors.","source_id_and_acronym":"CTR20202643","lead_sponsor":"Baochuan Biomedical Technology (Shanghai) Co., Ltd.","biomarkers":" BRAF • CUX1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"2066cb80-e597-4905-83af-abef784ab49c","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=0cff68ec3e93480e8b124ea3d7b02ce6","created_at":"2026-06-27T04:17:41.135Z","updated_at":"2026-06-27T04:17:41.135Z","phase":"Phase 1","brief_title":"Safety and tolerability study of HL-085 in combination with vemurafenib for the treatment of BRAF V600-mutant advanced solid tumors","source_id_and_acronym":"CTR20180314","lead_sponsor":"Shanghai Kezhou Pharmaceutical Research \u0026 Development Co., Ltd. / Tianjin Binjiang Pharmaceutical Research \u0026 Development Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 08/17/2018","start_date":" 08/17/2018","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"2e1f069d-d5fc-445e-beba-df86c19198d9","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=6547cb83ce444fc39b50dd42b725646a","created_at":"2026-06-27T03:55:30.823Z","updated_at":"2026-06-27T03:55:30.823Z","phase":"Phase 1","brief_title":"Phase I/IIa Clinical Study of XNW7201 Tablets","source_id_and_acronym":"CTR20191827","lead_sponsor":"Suzhou Sinov Pharmaceutical Technology Co., Ltd.","biomarkers":" KRAS • BRAF • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E","tags":["KRAS • BRAF • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"2e4e8299-dfa1-48ee-b3a5-0afadcab3959","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=12ff39b2f9c94a5fb211263707f6dcae_p","created_at":"2026-06-27T04:02:14.665Z","updated_at":"2026-06-27T04:02:14.665Z","phase":"Phase 1","brief_title":"Phase I clinical study of RX208 in patients with advanced malignant solid tumors","source_id_and_acronym":"CTR20192492","lead_sponsor":"Suzhou Runxin Biotechnology Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF positive"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"32670e2c-92e1-47d3-9e55-ee1e2e17fc03","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=83204095d3d943dfac1bc1699b236daf","created_at":"2026-06-27T04:28:46.080Z","updated_at":"2026-06-27T04:28:46.080Z","phase":"Phase 1","brief_title":"A phase I clinical study evaluating the safety and tolerability of CEL001 injection for the treatment of advanced solid tumors.","source_id_and_acronym":"CTR20252455","lead_sponsor":"Guangzhou Xiling Biotechnology Co., Ltd.","biomarkers":" EGFR • PD-L1 • BRAF • ALK • TMB • MSI • FGFR2 • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • TMB-H • MSI-H/dMMR • BRAF V600 • FGFR2 mutation • ALK mutation","tags":["EGFR • PD-L1 • BRAF • ALK • TMB • MSI • FGFR2 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • TMB-H • MSI-H/dMMR • BRAF V600 • FGFR2 mutation • ALK mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"6bd76e22-8cc1-4ec8-a9d6-49cf3f103fc4","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=06c70711593d4475bdc2482a5998afc2_p","created_at":"2026-06-27T04:22:03.572Z","updated_at":"2026-06-27T04:22:03.572Z","phase":"","brief_title":"Phase Ib/II clinical trial of Anmimuzam injection for the treatment of advanced colorectal cancer","source_id_and_acronym":"CTR20181002","lead_sponsor":"Shanghai Seron Biotechnology Co., Ltd. / Institute of Biotechnology, Academy of Military Medical Sciences of the Chinese People's Liberation Army","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600E • RAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • RAS wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"a7844c11-3c10-4548-b4b9-6a21451ec9d3","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=e2d0bcb9405748a3b7b8f1a7ae8c125c","created_at":"2026-06-27T04:04:27.534Z","updated_at":"2026-06-27T04:04:27.534Z","phase":"Phase 1","brief_title":"JMT-101 Phase I Clinical Study","source_id_and_acronym":"CTR20160904","lead_sponsor":"Shanghai Jinmante Biotechnology Co., Ltd.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF wild-type • RAS mutation • RAS wild-type • EGFR positive • BRAF V600 wild-type","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF wild-type • RAS mutation • RAS wild-type • EGFR positive • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 259","initiation":"Initiation: 04/11/2017","start_date":" 04/11/2017","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"c1ce0299-c053-47cf-b917-763f2e844233","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=06ed7606a6a24d3cb0b26797780b80f2","created_at":"2026-06-27T04:29:11.204Z","updated_at":"2026-06-27T04:29:11.204Z","phase":"Phase 1/2","brief_title":"A Phase I/II clinical trial of GV20-0251 injection in patients with advanced solid tumors.","source_id_and_acronym":"CTR20252531","lead_sponsor":"Shanghai Xunbaihui Biotechnology Co., Ltd.","biomarkers":" EGFR • ALK • MET","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • MET exon 14 mutation • MET mutation","tags":["EGFR • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • MET exon 14 mutation • MET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"c7d2678e-75cd-4736-ab60-1fab3263c2a9","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=1ba96a7f062f4775843c83de1b27e963_p","created_at":"2026-06-27T04:03:08.870Z","updated_at":"2026-06-27T04:03:08.870Z","phase":"Phase 2","brief_title":"Phase IIa clinical trial of Anmimuzam injection for the treatment of advanced colorectal cancer","source_id_and_acronym":"CTR20192641","lead_sponsor":"Shanghai Seron Biotechnology Co., Ltd. / Institute of Biotechnology, Academy of Military Medical Sciences of the Chinese People's Liberation Army","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type • RAS wild-type • NRAS wild-type"],"overall_status":"Recruiting","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"d46a0a6e-eb8a-4147-bcc1-24a6bcf728d1","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=e2f339e96b35468eac4fb0c316126a95","created_at":"2026-06-27T04:26:41.251Z","updated_at":"2026-06-27T04:26:41.251Z","phase":"Phase 3","brief_title":"A Phase III clinical trial of FCN-159 tablets in pediatric patients with low-grade gliomas who are positive for KIAA1549-BRAF fusion or BRAF V600E mutation.","source_id_and_acronym":"CTR20252088","lead_sponsor":"Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. / Chongqing Fuchuang Pharmaceutical Research Co., Ltd.","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • vincristine • Fumaining (luvometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/25/2025","start_date":" 06/25/2025","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"}]